Clinical trials
Immune Checkpoint Therapy clinical trials
Below are recruiting immune checkpoint therapy clinical trials, each written for real people, not researchers. We’re tracking 153 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06408688RecruitingPhase 4
Mistletoe extract added to immunotherapy for advanced solid tumors
This trial tests whether adding mistletoe extract (Iscador) to standard immunotherapy can make the treatment safer and boost the immune system's response against advanced solid tumors (excluding skin cancer). If you are already receiving or about to start a checkpoint inhibitor, this study may help understand if the combination works better.
BadenAges 18 years+ - NCT06337097Recruiting
Monitoring heart enzyme during immunotherapy
This study is for people starting immunotherapy with checkpoint inhibitors. It checks a heart enzyme (troponin) to see if the treatment affects your heart, so your doctor can monitor and manage any changes early.
Houston, TexasAges 18 years+ - NCT07230639RecruitingPhase 2
Shorter radiation with chemo and immunotherapy for high-risk colon cancer
This trial tests a shorter course of radiation combined with chemotherapy and an immunotherapy drug (PD-1 inhibitor) for people with a specific type of high-risk colon cancer that has not spread. The goal is to see if this approach can shrink the tumor before surgery and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT07748325RecruitingPhase 2
Checking if immunotherapy after surgery helps prevent lung cancer return
This trial is for people with non-small cell lung cancer who have already had immunotherapy and chemotherapy before surgery, followed by complete removal of the tumor. It tests whether continuing immunotherapy after surgery (adjuvant treatment) can lower the risk of cancer coming back compared to just watching and waiting.
Chengdu, SichuanAges 18–75 - NCT03899428RecruitingPhase 2
Immune therapy versus targeted therapy for advanced liver cancer
This trial compares an immune “checkpoint” medicine to a targeted cancer medicine in people with advanced liver cancer who have hepatitis B in the blood. It aims to lower hepatitis B surface antigen (HBsAg) levels and see which approach works better and is safest.
Hong Kong, Hong Kong SARAges 18 years+ - NCT04807127Recruiting
Testing blood and lung fluid markers for lung side effects
This study tries to find early warning markers in lung fluid collected during a bronchoscopy (a camera test of the airways). The goal is to better spot and understand lung inflammation that can happen after immune checkpoint cancer treatments.
Leuven, Flemish BrabantAges 18–120 - NCT05941741RecruitingPhase 3
Tested low-dose radiation plus cadonilimab for nasopharyngeal cancer
This Phase 3 trial studies whether adding low-dose radiation to cadonilimab (an immune therapy) can improve outcomes for people newly diagnosed with a specific type and stage of nasopharyngeal cancer. If you’re eligible, it may offer a new treatment approach and helps researchers confirm whether it works best.
Guangzhou, GuangdongAges 18–70 - NCT06841705RecruitingPhase 2
Early vedolizumab as first treatment for colitis from immunotherapy
This trial tests if giving vedolizumab early can help control severe diarrhea and colon inflammation caused by immunotherapy (a type of cancer treatment). It may offer a new option for people who develop these side effects.
Boston, MassachusettsAges 18 years+ - NCT06923345RecruitingPhase 2
Modified long-course radiation and chemo with immunotherapy for rectal cancer
This trial tests a treatment plan involving radiation, chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with a specific type of high-risk rectal cancer. The goal is to see if this combination helps shrink the tumor before surgery.
Guangzhou, GuangdongAges 18–75 - NCT06958432RecruitingPhase 2/Phase 3
Short-course radiation plus chemo and immunotherapy for rectal cancer
This trial tests a treatment plan that uses a short course of radiation to the lymph nodes-sparing area, followed by chemotherapy and an immunotherapy drug (PD-1 inhibitor) for people with a specific type of mid or low rectal cancer (pMMR/MSS). The goal is to see if this approach can shrink the tumor and improve outcomes without needing extensive surgery.
Guangzhou, GuangdongAges 18–75 - NCT07279077RecruitingPhase 2
Low-dose radiation with chemo and immunotherapy for high-risk colon cancer
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (PD-1 inhibitor) for people with a specific type of high-risk colon cancer that has not spread. The goal is to see if this approach can shrink the tumor before surgery and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT07088081Enrolling by invitation
Immunotherapy drugs for advanced liver cancer
This trial tests two types of immunotherapy (atezolizumab with bevacizumab or durvalumab with tremelimumab) for people with advanced liver cancer that hasn't been treated with systemic therapy before. It aims to see if these treatments are safe and effective.
Cairo, AbbasyaAges 18 years+ - NCT04322617RecruitingPhase 2/Phase 3
Anlotinib plus immunotherapy for lung cancer after first treatment
This trial studies an oral targeted medicine (anlotinib) combined with an immunotherapy (checkpoint inhibitor) for lung cancer that did not respond to first-line chemo-immunotherapy. It may help shrink tumors and improve disease control after standard treatment has failed.
Changsha, HunanAges 18 years+ - NCT05037825Recruiting
Study gut microbes with immune therapy in several solid cancers
This trial looks at how the gut microbiome (the bacteria in your digestive system) relates to outcomes when you take standard immune “checkpoint” cancer medicines. If you’re eligible, they’ll collect stool samples while you receive treatment for certain cancers.
Elizabethtown, KentuckyAges 18 years+ - NCT07034326RecruitingPhase 2/Phase 3
Acupuncture plus immunotherapy after lung cancer surgery
This trial explores whether adding electroacupuncture (a gentle needle treatment with mild electric pulses) to standard immunotherapy after lung cancer surgery can help prevent the cancer from coming back. It is designed for people with early-stage non-small cell lung cancer who have already had chemotherapy.
TianjinAges 18–80 - NCT06647134Recruiting
Understanding how immunotherapy side effects affect daily life
This study is for people whose immunotherapy (a type of cancer treatment) caused joint pain, swelling, or muscle stiffness. Researchers want to talk to you about how these side effects have affected your life, so they can better understand and help others in the future.
Houston, TexasAges 18 years+ - NCT07639138RecruitingPhase 2
Lenalidomide with targeted therapy and immunotherapy for advanced liver cancer
This trial tests whether adding lenalidomide (a drug that boosts the immune system) to your current targeted therapy and immunotherapy can help advanced liver cancer that has progressed after previous treatments. You would be eligible if your cancer has already been treated with at least two prior drug combinations and initially responded before growing back.
Beijing, No. 1 Shuaifuyuan, Dongcheng District, Beijing, ChinaAges 18–75 - NCT06635954Recruiting
Blood test to predict response to immunotherapy
This study is testing a blood test (Episwitch CiRT®) that looks at your DNA to see if it can predict whether you will respond to a type of immunotherapy called PD-(L)-1 checkpoint inhibitors. The goal is to see if this test is accurate across many different types of cancer.
Norwich, ConnecticutAges 18 years+ - NCT06958419RecruitingPhase 2/Phase 3
Short radiation plus targeted drugs for advanced colon cancer
This trial tests a combination of short-course radiation, chemotherapy, targeted therapy (bevacizumab), and an immunotherapy drug (PD-1 inhibitor) for people with advanced colorectal cancer that has spread and is not curable with surgery. It aims to see if this approach can help shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT04793737Recruiting
Targeted radiation for melanoma that won’t respond to immunotherapy
This study tests a very focused form of radiation for melanoma that has spread and has stopped responding to PD-1 (and sometimes CTLA-4) immunotherapy. It may help by shrinking progressing spots while keeping the immune treatment going.
StockholmAges 18 years+ - NCT06132984Recruiting
Heart MRI monitoring for immunotherapy-related heart issues
This study uses heart MRIs to monitor women with gynecologic cancers who are about to start immunotherapy. The goal is to detect early signs of heart problems so doctors can take action quickly.
Chengdu, SichuanAges 18–75 - NCT07661459RecruitingPhase 2
Antihistamine and aspirin with immunotherapy for solid tumors
This trial tests whether taking a daily antihistamine (like Claritin) and a daily aspirin alongside your immunotherapy can make the treatment work better. It's for people with solid tumors who are about to start a PD-1 or PD-L1 blocker.
Lexington, KentuckyAges 18–99 - NCT06240689RecruitingPhase 2
Immune maintenance therapy after chemoradiotherapy for head and neck cancer
This trial tests whether adding an immune checkpoint inhibitor (a drug that helps your immune system fight cancer) as maintenance therapy after chemoradiotherapy improves outcomes for people with locally advanced head and neck cancer. It specifically looks at a marker in your blood (CD8Tex cells) to see if you might benefit.
Hangzhou, ZhejiangAges 18–75 - NCT07216495Recruiting
Exercise study for early-stage triple-negative breast cancer patients
This study tests if aerobic exercise can help women and men with stage 2 or 3 triple-negative breast cancer who are getting chemotherapy and immunotherapy before surgery. It aims to see if exercise improves treatment outcomes and quality of life.
Houston, TexasAges 18 years+
Hear when a new Immune Checkpoint Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immune checkpoint therapy?
- Yes. Clin2 currently lists 153 recruiting immune checkpoint therapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immune checkpoint therapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immune checkpoint therapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.